Ribociclib clinical trials

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study looks at a new drug, AZD8421, for advanced breast cancer (ER+ HER2- type) and a type of ovarian cancer. It checks how safe and effective it is, sometimes alone and sometimes with other cancer medicines.

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

This study is looking at a new combination of medicines for advanced breast cancer that has stopped responding to hormone therapy. It aims to see if combining inavolisib with ribociclib and fulvestrant works better than the current treatment.

Study of INCB123667 in Subjects With Advanced Solid Tumors

This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

This study is looking at new drug combinations to treat certain types of brain tumours in children and young adults. It aims to see if combining ribociclib with either everolimus or temozolomide can help patients live longer and improve their health.

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

This study looks at a new drug, ECI830, for advanced breast cancer and other solid tumors. Researchers want to see if it's safe and effective, both alone and with other common cancer medicines.

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

This study is looking for new ways to treat advanced melanoma, a type of skin cancer. It's testing combinations of new medicines (LXH254, LTT462) with existing ones (Trametinib, Ribociclib) in people whose melanoma has progressed after previous treatments. The goal is to see how well these new combinations work and if they are safe.

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.

J6M-MC-JSGD: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

This study is for adults with advanced breast cancer that is HR+, HER2-, and has a specific gene change (PIK3CA mutation), who haven't had previous treatment for advanced disease. It tests a new drug called tersolisib alongside standard hormone therapy and other targeted drugs to see if it can help stop the cancer from growing.

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.

Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in breast cancer, with positive hormone receptors and negative HER2 status, in newly diagnosed, not immediately operable (or wishing to avoid surgery), elderly patient

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

This study looks at adding a drug called ribociclib to standard hormone therapy for people with early-stage breast cancer. It aims to see if this combination works better at preventing cancer from coming back and if it's safe for patients.